MARKET

GBIO

GBIO

Generation Bio Co.
NASDAQ
5.96
-0.48
-7.45%
Closed 16:01 02/08 EST
OPEN
6.46
PREV CLOSE
6.44
HIGH
6.46
LOW
5.94
VOLUME
134.45K
TURNOVER
--
52 WEEK HIGH
9.59
52 WEEK LOW
3.545
MARKET CAP
354.16M
P/E (TTM)
-2.5123
1D
5D
1M
3M
1Y
5Y
JMP Securities Maintains Market Outperform on Generation Bio, Lowers Price Target to $7
Benzinga · 01/19 12:22
--JMP Securities Adjusts Price Target on Generation Bio to $7 From $11, Maintains Market Outperform Rating
--JMP Securities Adjusts Price Target on Generation Bio to $7 From $11, Maintains Market Outperform Rating
MT Newswires · 01/19 08:46
Can Generation Bio Co. (GBIO) Climb 184% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 183.8% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions migh...
Zacks · 12/05/2022 14:55
Imago BioSciences, GrafTech International And Some Other Big Stocks Moving Higher On Monday
Benzinga · 11/21/2022 16:27
Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday
Benzinga · 11/21/2022 10:58
Wall Street Analysts Think Generation Bio Co. (GBIO) Could Surge 176%: Read This Before Placing a Bet
The consensus price target hints at a 176% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witne...
Zacks · 11/17/2022 14:55
Canaccord Genuity Initiates Coverage On Generation Bio with Buy Rating, Announces Price Target of $9
Benzinga · 11/08/2022 09:58
--Canaccord Genuity Starts Generation Bio at Buy With $9 Price Target
--Canaccord Genuity Starts Generation Bio at Buy With $9 Price Target
MT Newswires · 11/08/2022 08:39
More
About GBIO
Generation Bio Co. is genetic medicines to provide treatments of rare and prevalent diseases. The Company through its non-viral genetic medicine platform, is engaged in developing genetic medicines to provide genetic payloads, which include large and multiple genes to a range of cell types across a range of diseases. It is comprised of three component technologies: ceDNA, ctLNP and ceDNA manufacturing process. ceDNA is an engineered, double-stranded, linear, covalently closed-ended deoxyribonucleic acid (DNA) construct, which includes the gene of interest and associated regulatory sequences. It has produced ceDNA constructs of approximately eight kilobases. Its ctLNP delivery system builds upon clinically validated lipid nanoparticles and is designed to allow for repeat dosing of a genetic payload without stimulating an immune response, such as antibody production. Its ceDNA manufacturing process uses its own cell-free rapid enzymatic synthesis (RES) to produce ceDNA.

Webull offers kinds of Generation Bio Co stock information, including NASDAQ:GBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GBIO stock methods without spending real money on the virtual paper trading platform.